Pompe Disease – Epidemiology – Mature Markets

Clarivate Epidemiology’s coverage of Pompe disease comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of Pompe disease for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years. 

Clarivate Epidemiology’s Pompe disease forecast will answer the following questions:

  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of Pompe disease over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

Clarivate Epidemiology forecasts three patient populations, as follows:

  • Diagnosed juvenile and adult prevalent cases of Pompe disease.
  • Diagnosed infantile prevalent cases of Pompe disease.
  • Diagnosed prevalent cases of Pompe disease.

Note: Coverage may vary by country.

Table of contents

  • Pompe Disease - Epidemiology - Mature Markets
    • Epidemiology data
    • Methods
      • Literature review (studies included in/excluded from the analyses of Pompe disease)
      • Diagnosed prevalent cases
      • Diagnosed prevalent cases of infantile-onset Pompe disease
      • Diagnosed prevalent cases of late-onset Pompe disease
      • Risk / protective factors applied to disease forecast models
    • Reference materials
      • Bibliography
      • Glossary
      • Abbreviation table

Login to access report